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The E5 proteins of bovine papillomavirus type 1 (BPV-1) and human papillomavirus type 16 (HPV-16) are small (44–83 amino acids),
hydrophobic polypeptides that localize to membranes of the Golgi apparatus and endoplasmic reticulum, respectively. While the oncogenic
properties of BPV-1 E5 have been characterized in detail, less is known about HPV-16 E5 due to its low expression in mammalian cells.
Using codon-optimized HPV-16 E5 DNA, we have generated stable fibroblast cell lines that express equivalent levels of epitope-tagged
BPV-1 and HPV-16 E5 proteins. In contrast to BPV-1 E5, HPV-16 E5 does not activate growth factor receptors, phosphoinositide 3-kinase or
c-Src, and fails to induce focus formation, although it does promote anchorage-independent growth in soft agar. These variant activities are
apparently unrelated to differences in intracellular localization of the E5 proteins since retargeting HPV-16 E5 to the Golgi apparatus does not
induce focus formation.
D 2004 Elsevier Inc. All rights reserved.
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Bovine papillomavirus type 1 (BPV-1) is a double-
stranded DNA tumor virus that induces benign neoplasia in
cattle (Lancaster and Olson, 1982) and horses (Carr et al.,
2001), and has been used as a model system to study
papillomavirus-mediated transformation in vitro (Chen et al.,
1982; Dvoretzky et al., 1980; Lowy et al., 1980). Themajor in
vitro transforming protein of BPV-1 is E5 (BPV E5) (DiMaio
et al., 1986; Groff and Lancaster, 1986; Schiller et al., 1986;
Yang et al., 1985), a small (44 amino acids), hydrophobic
polypeptide that localizes to membranes of the Golgi
apparatus (Burkhardt et al., 1989; Schapiro et al., 2000).
The transforming activity of BPV E5 derives in part from its
ability to induce trans-phosphorylation and constitutive
activation of platelet-derived growth factor receptors
(PDGF-Rs) that form a complex with BPV E5 dimers0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: schleger@georgetown.edu (R. Schlegel).(Drummond-Barbosa et al., 1995; Goldstein et al., 1994;
Lai et al., 1998; Petti et al., 1991). In addition, BPV E5 binds
to the 16-kDa pore-forming subunit of the vacuolar H+-
ATPase (16K) (Goldstein et al., 1991) and inhibits normal
acidification of the Golgi lumen by interfering with H+
transport (Schapiro et al., 2000). The interaction of BPV E5
with 16K may contribute to E5-mediated transformation,
since the Q17S and L26A BPV E5 point mutants inhibit
Golgi acidification and transform fibroblasts (Schapiro et al.,
2000), but do not activate the PDGF-R because they are
defective in PDGF-R binding or homodimer formation,
respectively (Adduci and Schlegel, 1999; Sparkowski et al.,
1996). These E5 mutants activate heterodimeric phosphoino-
sitide 3-kinase (PI 3-K) and c-Src in a PDGF-R-independent
manner, and c-Src activation is required for transformation by
L26A E5 (Suprynowicz et al., 2000, 2002).
Epidemiological studies have shown that high-risk human
papillomaviruses (HPVs) are the primary causative agent of
cervical cancer worldwide, and that HPV E5, E6 and E7
genes play important roles in HPV pathogenesis (zur Hausen,05) 102–113
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16 (HPV-16) have been studied extensively, considerably less
is known about the biological activity of its E5 gene product
(HPV-16 E5). Like BPV E5, HPV-16 E5 is a small (83 amino
acids), hydrophobic protein that localizes to intracellular
membranes (Conrad et al., 1993; Disbrow et al., 2003), and
can transform fibroblasts to grow in soft agar (Leechanachai
et al., 1992; Pim et al., 1992; Straight et al., 1993). HPV-16 E5
also is mitogenic in primary keratinocytes, especially in
cooperation with epidermal growth factor (EGF) and HPV-16
E7 (Bouvard et al., 1994; Straight et al., 1993; Valle and
Banks, 1995; Venuti et al., 1998). The latter finding may be
related to the ability of HPV-16 E5 to enhance HPV-16-
mediated reprogramming of terminally differentiating kera-
tinocytes to undergo DNA synthesis in order to support viral
DNA amplification (Genther et al., 2003). HPV-16 E5 stably
associates with the 16KV-ATPase protein (Adam et al., 2000;
Ashby et al., 2001; Conrad et al., 1993; Rodriguez et al.,
2000), and can bind to the EGF receptor (EGF-R), PDGF-R
and colony-stimulating factor-1 receptor (Hwang et al.,
1995). The association of wild-type (wt) HPV-16 E5 with
16K may interfere with vacuolar H+-ATPase function and
inhibit endosome acidification (Adam et al., 2000; Briggs et
al., 2001; Straight et al., 1995), although an inhibitory effect
on endocytic trafficking also appears likely (Ashby et al.,
2001; Thomsen et al., 2000). The resulting delay in endosome
acidification (Straight et al., 1993, 1995), or delay in the
fusion of early endocytic vesicles with acidic late endosomes
(Rodriguez et al., 2000; Thomsen et al., 2000), may be
responsible for enhanced EGF-R activation by EGF in cells
expressing HPV-16 E5 (Crusius et al., 1998; Pim et al., 1992;
Rodriguez et al., 2000; Straight et al., 1993).
The inability of previous studies to detect expression of
the HPV-16 E5 protein, unless transiently overexpressed in
COS cells (Conrad et al., 1993; Hwang et al., 1995),
undoubtedly has hampered characterization of its biological
activity, and may account for discrepancies in its reported
properties. Recently, Disbrow et al. (2003) have shown that
HPV-16 E5 is expressed poorly in mammalian cells due to a
high incidence (40%) of infrequently used codons, and that
expression can be increased greatly by substituting codons
more commonly used to encode the same amino acids. In
the present study, we use codon-optimized HPV-16 E5
DNA to generate fibroblast cell lines that stably express
epitope-tagged HPV-16 E5 and BPV E5 proteins at the same
level. This system enables us to directly determine whether
HPV-16 E5 exhibits oncogenic properties of BPV E5 in
cells where the behavior of BPV E5 is well characterized.Fig. 1. Expression levels of BPV E5 and HPV-16 E5 in NIH 3T3 cell lines.
Anti-AU1 Western blot of anti-AU1 immunoprecipitates from stable cell
lines expressing AU1-tagged HPV-16 E5, BPV E5 or harboring the empty
JS55 expression vector. Immunoprecipitates were prepared from 1.5 or 0.75
mg of cell lysate protein. Molecular mass markers (in kDa) are indicated on
the left.Results
Growth factor receptor activation
To investigate whether HPV-16 E5 activates signal
transduction proteins known to be activated by BPV E5,we generated NIH 3T3 cell lines that stably express the E5
proteins in equal amounts. NIH 3T3 cells were chosen for
this purpose since the signaling properties of BPV E5 have
been characterized extensively in these cells (Goldstein et
al., 1994; Lai et al., 1998; Petti et al., 1991; Sparkowski et
al., 1996; Suprynowicz et al., 2000, 2002). Normally, the
HPV-16 E5 gene is expressed poorly in mammalian cells
due to a high incidence (40%) of infrequently used codons,
but expression can be increased more than sixfold by
replacing these codons with more commonly used counter-
parts (Disbrow et al., 2003). As shown in Fig. 1, codon-
optimized HPV-16 E5 and wt (not codon-optimized) BPV
E5 proteins were present at equivalent levels when epitope-
tagged and expressed in 3T3 cell lines. No E5 expression
was detected in a control cell line harboring the empty JS55
expression vector. The immunoprecipitation and immuno-
blotting protocol used to detect E5 was not saturated by the
amount of cell lysate employed in these measurements (1.5
mg), since identical results were obtained when E5 proteins
were immunoprecipitated from half as much lysate (0.75
mg; Fig. 1). E5 expression remained stable in these cell lines
for at least 30 passages (data not shown).
The ability of BPV E5 to induce tyrosine phosphoryla-
tion and sustained activation of the PDGF-R is well
documented (Drummond-Barbosa et al., 1995; Goldstein
et al., 1994; Lai et al., 1998; Petti et al., 1991). In our BPV
E5-expressing cell line, the PDGF-R (immature form) was
constitutively activated, especially after 24 h of serum
starvation. In contrast, persistent activation of the PDGF-R
was not observed in cell lines expressing HPV-16 E5 or
containing the empty JS55 expression vector (Fig. 2A).
Serum-starved HPV-16 E5-expressing cells and vector
control cells exhibited equally substantial activation of the
PDGF-R (mature form) when acutely stimulated with PDGF
for 10 min (Fig. 2A), thereby demonstrating that HPV-16 E5
did not inhibit receptor activation. It is noteworthy that
HPV-16 E5 also did not enhance PDGF-R activation in the
presence of PDGF (Fig. 2A), given its ability to increase the
recycling of ligand-bound EGF-Rs to the plasma membrane
in keratinocytes (Straight et al., 1993, 1995).
Fig. 2. Effect of E5 proteins on acute and constitutive growth factor
receptor activation. (A) PDGF-R activation. Tyrosine-phosphorylated
proteins were immunoprecipitated (from equal amounts of cell protein)
from NIH 3T3 cell lines expressing HPV-16 E5, BPV E5, or from control
cells containing the empty JS55 vector. Prior to lysis in SDS, cells were
cultured for 24 h in medium containing 0.1% FBS (FBS), or in medium
containing 10% FBS and 20 ng/ml PDGF (+FBS; +GF, 1 day). Half the
cells in 0.1% FBS were acutely stimulated with 20 ng/ml PDGF for 10 min
immediately preceding lysis (FBS; +GF, 10 min). The immunoprecipi-
tates were analyzed on anti-PDGF-R Western blots to detect tyrosine-
phosphorylated PDGF-Rs. The upper and lower bands correspond to
mature and immature forms of the PDGF-R, respectively. Molecular mass
marker (in kDa) is shown on the left. (B) EGF-R activation. Anti-
phosphotyrosine immunoprecipitates were analyzed on anti-EGF-R West-
ern blots to detect tyrosine-phosphorylated EGF-Rs. EGF (50 ng/ml) was
added to cell cultures for 24 h (+FBS; +GF, 1 day) or for 10 min (FBS;
+GF, 10 min) before lysis. (C) Proliferation assays. The proliferation of
NIH 3T3 cells and 3T3 cell lines in medium containing 0.3% FBS was
measured for 3 days as described in Materials and methods.
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phosphorylation and activation of the EGF-R in response
to EGF in NIH 3T3 fibroblasts that overexpress exogenous
EGF-Rs (Pim et al., 1992) and in epithelial cells, which
possess large numbers of endogenous EGF-Rs (Crusius et
al., 1998; Gottlieb et al., 1992; Rodriguez et al., 2000;
Straight et al., 1993). EGF-R tyrosine phosphorylation was
measured in our HPV-16 E5-expressing fibroblasts to
determine whether the higher level of HPV-16 E5 expres-
sion afforded by codon optimization could induce or
enhance activation of endogenous (not overexpressed)
EGF-Rs. However, we found that HPV-16 E5 did not
increase EGF-R activation, compared to JS55 control cells,
under a variety of growth conditions: serum starvation,acute stimulation with EGF (10 min) and treatment with
EGF for 24 h (Fig. 2B). The decreased level of EGF-R
activation in acutely stimulated BPV E5-expressing cells
(Fig. 2B) was the result of a reduction in the total number of
EGF-Rs present (data not shown).
To screen for growth factor receptor activation in a
functional assay, we monitored the proliferation of E5-
expressing cell lines in medium containing a low level
(0.3%) of fetal bovine serum (FBS) for a period of 3 days.
We previously have correlated proliferation in this assay
with ligand-independent growth factor receptor activation
by BPV E5 and the sis oncogene (Suprynowicz et al.,
2000). Furthermore, NIH 3T3 cells have receptors for
PDGF, EGF, insulin, basic fibroblast growth factor and
insulin-like growth factor, since these ligands all induce
proliferation in this assay (Suprynowicz et al., 2000, 2002).
In the present study, the number of BPV E5-expressing
cells increased by more than 200% in 3 days, due to BPV
E5 activation of the PDGF-R, whereas normal NIH 3T3
cells and vector controls actually decreased in number
during the same period (Fig. 2C). HPV-16 E5-expressing
cells behaved in the same manner as the control cells (Fig.
2C), indicating that HPV-16 E5 did not activate a growth
factor receptor capable of stimulating proliferation. There-
fore, a variety of assays capable of detecting growth factor
receptor activation by BPV E5 do not detect activation by
HPV-16 E5, even though the two E5 proteins are present at
the same level.
Activation of PI 3-K and c-Src
A mutational analysis of BPV E5 has shown that it can
activate PI 3-K and c-Src independently of growth factor
receptor activation (Suprynowicz et al., 2000, 2002). We
investigated whether HPV-16 E5 can activate PI 3-K by
measuring tyrosine phosphorylation of the PI 3-K 85 kDa
regulatory subunit (p85) in E5-expressing and control cell
lines under conditions of serum starvation and growth. p85
tyrosine phosphorylation is known to induce PI 3-K
activation (Shepherd et al., 1998), and has been correlated
with BPV E5-mediated PI 3-K activation in NIH 3T3 cells
(Suprynowicz et al., 2000). In agreement with our previous
report, p85 tyrosine phosphorylation was dramatically
elevated in serum-starved cells expressing BPV E5 relative
to control cells harboring the empty expression vector (Fig.
3, 0.1% FBS). Additionally, BPV E5 increased p85 tyrosine
phosphorylation in exponentially growing cells (Fig. 3, 10%
FBS). However, in the presence of both 0.1% FBS and 10%
FBS, cells expressing HPV-16 E5 exhibited a low level of
p85-associated phosphotyrosine that was indistinguishable
from the vector control (Fig. 3). The similarity of p85 (and
PDGF-R) tyrosine phosphorylation levels in these cells after
24 h in the presence of 0.1% and 10% FBS (Figs. 2A and 3)
reflects the down-regulation of PDGF-R expression that
occurs in the continuous presence of growth factors (Lih et
al., 1996; Vaziri and Faller, 1995).
Table 1
E5 activation of c-Src
Cell linea Src kinase activity (% of 3T3)b
3T3 100 F 4
3T3/16 E5 117 F 13
3T3/JS55 97 F 11
3T3/BPV E5 193 F 24
a Cells were grown in 0.1% FBS for 24 h.
Fig. 3. E5 activation of PI 3-K. Tyrosine-phosphorylated proteins were
immunoprecipitated (from equal amounts of cell protein) from NIH 3T3
cell lines that were cultured for 24 h in medium supplemented with 0.1%
FBS, 10% FBS, 10% FBS + EGF (50 ng/ml), or 10% FBS + PDGF (20 ng/
ml). The immunoprecipitates were analyzed on immunoblots labeled with
antibodies recognizing the 85-kDa regulatory subunit of heterodimeric
PI 3-K. Molecular mass markers (in kDa) are shown on the left.
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lines following treatment with 10% FBS and PDGF for 24
h, resulting from ligand-induced PDGF-R activation at the
plasma membrane, and this level of phosphorylation was
not further increased by HPV-16 E5 (Fig. 3, 10% FBS +
PDGF). In contrast, treatment with 10% FBS and EGF did
not increase p85 tyrosine phosphorylation in control cells
or in cells expressing HPV-16 E5 (Fig. 3, 10% FBS +
EGF). PDGF and EGF differentially modulate p85
tyrosine phosphorylation in NIH 3T3 cells because the
PDGF-R and EGF-R utilize different mechanisms to
activate PI 3-K. The cytoplasmic protein tyrosine kinase
domain of the activated PDGF-R contains specific
phosphotyrosine docking sites for p85 at Y740 and
Y751. As a consequence of binding to these sites, p85
becomes tyrosine phosphorylated and the 110-kDa cata-
lytic subunit of PI 3-K is activated (Valius and Kazlauskas,
1993). These docking sites are not present in the EGF-R,
which activates PI 3-K through Ras and the Gab1 adapter
protein without p85 phosphorylation (Holgado-Madruga
and Wong, 2004).
The effect of E5 proteins on c-Src tyrosine kinase
activity was quantified in serum-starved cell lines using a
procedure in which a selective peptide substrate (Cheng et
al., 1992) is radioactively phosphorylated by anti-Src
immunoprecipitates. This assay previously has been used
to demonstrate activation of c-Src by BPV E5 in NIH 3T3
cells (Suprynowicz et al., 2002). Serum starvation was
employed to lower the overall level of c-Src kinase
activity, so that any potential activation by E5 proteins
would be more apparent. As shown in Table 1, BPV E5
increased c-Src kinase activity twofold relative to JS55
control cells. The same level of c-Src activation has been
observed during acute PDGF stimulation of serum-starved
NIH 3T3 cells (Suprynowicz et al., 2002). In contrast,
HPV-16 E5-expressing cells exhibited only slightly
increased (1.2-fold) Src kinase activity (Table 1). We
conclude that HPV-16 E5 does not share the ability of
BPV E5 to activate PI 3-K and c-Src independently of
growth factor receptor activation.Fibroblast transformation
The capacity of wt BPV E5 and numerous mutants that
are defective for PDGF-R activation to transform fibroblasts
has been demonstrated using focus formation assays, in
which normal NIH 3T3 cells are transfected with BPV E5
constructs (Adduci and Schlegel, 1999; Sparkowski et al.,
1994, 1996). More recently, we have shown that BPV E5-
expressing fibroblast cell lines can be screened for trans-
formation using a modified focus formation assay, in which
the cell lines are co-plated with normal NIH 3T3 cells
(Suprynowicz et al., 2002). When cell lines expressing
equal levels of BPV E5 and HPV-16 E5 were tested in the
modified focus assay, only the BPV E5 expressers formed
visible foci (Fig. 4A, 10% FBS). HPV-16 E5-expressing
cells also did not exhibit ligand-dependent focus formation,
since they did not form foci when the assay was conducted
in the continuous presence of EGF or PDGF (Fig. 4A, 10%
FBS + EGF and 10% FBS + PDGF). HPV-16 E5 previously
failed to transform NIH 3T3 cells in focus assays, although
the level of HPV-16 E5 expression relative to BPV E5 was
not shown (Disbrow et al., 2003; Straight et al., 1993).
However, codon-optimized HPV-16 E5 is biologically
active in NIH 3T3 cells, since it can transform the cells to
undergo anchorage-independent growth in soft agar. As
shown in Fig. 4B, NIH 3T3 cells expressing HPV-16 E5
formed much larger colonies in soft agar than did cells
harboring the empty expression vector. Cells expressing
BPV E5 also formed numerous large colonies. Consistent
with our finding that neither HPV-16 E5 nor BPV E5
enhances EGF-dependent EGF-R activation in NIH 3T3
cells (Fig. 2), the addition of purified EGF to soft agar
cultures did not differentially augment the growth of E5-
expressing cells relative to non-E5 expressors (Fig. 4B).
Golgi-targeted HPV-16 E5
The localization of BPV E5 in membranes of the Golgi
apparatus (Burkhardt et al., 1989; Schapiro et al., 2000)
appears to be essential for its ability to transform fibroblasts.
BPV E5 appended with the endoplasmic reticulum (ER)
retention sequence, KDEL, remains sequestered in the ER
(and cis Golgi) and is nontransforming (Sparkowski et al.,
1995). Since HPV-16 E5 is localized predominantly in ER
membranes (Disbrow et al., 2003), we asked whether HPV-
16 E5 might acquire transforming activity in focus assays if
directed to the Golgi compartment. For this analysis, we
Fig. 4. Transforming activities of E5 proteins. (A) Focus formation. Five hundred NIH 3T3 cells stably expressing HPV-16 E5, BPV E5, or harboring the empty
JS55 vector were co-cultured with 5  105 normal NIH 3T3 cells for 21 days with additions of fresh medium every 3 days. Where indicated, the medium was
supplemented with EGF (50 ng/ml) or PDGF (20 ng/ml). (B) Anchorage-independent growth in soft agar. NIH 3T3 cell lines expressing HPV-16 E5 or BPV E5
(or containing the empty JS55 expression vector) were maintained in agar for 4 weeks as described in Materials and methods. Where indicated, the culture
medium was supplemented with EGF (50 ng/ml).
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termed b16 E5-SDYQRLQ and bGolgi-16 E5Q. In 16 E5-
SDYQRL, the Golgi retrieval signal, SDYQRL (Roquemore
and Banting, 1998), is appended to the C terminus of AU1-
tagged, codon-optimized HPV-16 E5 (Fig. 5A). In Golgi-16
E5, AU1-tagged Q17G BPV E5 is appended to the N
terminus of codon-optimized HPV-16 E5 (Fig. 5A). The
Q17G BPV E5 mutant localizes to the Golgi apparatus
(Schapiro et al., 2000), but does not activate the PDGF-R
(Sparkowski et al., 1996), PI 3-K (Suprynowicz et al., 2000)
or c-Src (Suprynowicz et al., 2002), and does not transform
NIH 3T3 cells (Sparkowski et al., 1994). Anti-AU1
immunoprecipitation and immunoblot analysis showed that
both Golgi-targeted HPV-16 E5 constructs were expressed in
COS cells 48 h after transfection. The level of 16 E5-
SDYQRL expression was identical to that of HPV-16 E5,
while Golgi-16 E5was expressed at the same level as BPVE5
(Fig. 5B).
Native HPV-16 E5 (Adam et al., 2000; Ashby et al., 2001;
Conrad et al., 1993; Disbrow et al., 2003; Gieswein et al.,2003; Rodriguez et al., 2000) and BPV E5 (Andresson et al.,
1995; Burkhardt et al., 1987; Goldstein and Schlegel, 1990;
Goldstein et al., 1991) stably associates with the 16K pore-
forming subunit of the vacuolar H+-ATPase and forms
disulfide-linked homodimers in vivo. To demonstrate that
Golgi-targeted HPV-16 E5 proteins are biologically active,
we tested the ability of 16 E5-SDYQRL and Golgi-16 E5 to
bind 16K and to dimerize in COS cells. In cells co-transfected
with AU1-tagged E5 constructs and HA-tagged 16K, co-
immunoprecipitation experiments indicated that BPV E5,
HPV-16 E5 and the two Golgi-targeted HPV-16 E5 proteins
stably associate with 16K (Fig. 5C). 16K was not detected in
anti-AU1 immunoprecipitates if the cells were co-trans-
fected with HA-16K and the empty E5 expression vector
(Fig. 5C). In reducing SDS-polyacrylamide gels, HPV-16
E5, 16 E5-SDYQRL and Golgi-16 E5 were primarily
monomeric, while BPV E5 was in the form of monomers
and higher-order oligomers (Fig. 5D). In contrast, all of
these E5 proteins demonstrated an ability to form disulfide-
linked homodimers in nonreducing SDS gels (Fig. 5D).
Fig. 5. Golgi-targeted HPV-16 E5 constructs. (A) Schematic diagram. (B)
Expression in COS cells. Anti-AU1 immunoblot of anti-AU1 immunopre-
cipitates from COS-1 cells 48 h after transfection with plasmids encoding
AU1-taggedBPVE5, HPV-16 E5, or the Golgi-targeted E5 constructs 16 E5-
SDYQRL and Golgi-16 E5. Molecular mass markers (in kDa) are shown on
the left. (C) Association with the V-ATPase 16K subunit. Anti-HA
immunoblot of anti-AU1 immunoprecipitates from COS-1 cells 24 h after
co-transfection with plasmids encoding HA-tagged 16K and AU1-tagged
BPV E5, HPV-16 E5, or the Golgi-targeted E5 constructs 16 E5-SDYQRL
and Golgi-16 E5. Molecular mass marker (in kDa) is shown on the left. (D)
Dimerization. HPV-16 E5 and 16 E5-SDYQRL proteins were immunopre-
cipitated from COS-1 cells 24 h after transfection and analyzed on anti-AU1
Western blots (IP: AU1; IB: AU1). BPV E5 and Golgi-16 E5 proteins were
immunoprecipitated from [35S] methionine-labeled COS-1 cells 24 h after
transfection and analyzed by SDS polyacrylamide gel electrophoresis and
autoradiography (IP: AU1). Electrophoresis was carried out under reducing
conditions in the presence of h-mercaptoethanol (+ hME), or under
nonreducing conditions without h-mercaptoethanol ( hME). Molecular
mass markers (in kDa) are indicated on the left and right.
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Golgi-16 E5 was evaluated by immunofluorescence micro-
scopy in COS cells 24 h after transfection (Fig. 6). In
agreement with previous findings (Disbrow et al., 2003),
anti-AU1 labeling of HPV-16 E5-transfected cells yielded a
reticular pattern that co-localized with the ER membrane
protein, calnexin (David et al., 1993). In contrast, BPV E5
immunofluorescence was restricted to a discrete perinuclear
region that co-localized with fluorescently labeled wheat
germ agglutinin (WGA), a probe selective for the Golgi
apparatus (Virtanen et al., 1980). The level of nonspecific
background fluorescence was extremely low, since cells
transfected with the empty JS55 expression vector exhibited
negligible anti-AU1 immunofluorescence. 16 E5-SDYQRL
localized predominantly to a perinuclear region that labeled
with WGA, but also was present in the nuclear envelope in
most cells. Golgi-16 E5 exclusively co-localized with
WGA, and was not detected in the nuclear envelope or
ER. Therefore, the SDYQRL signal was effective in
directing much of HPV-16 E5 to the Golgi, while Q17G
BPV E5 was highly effective in imposing Golgi localization
on HPV-16 E5.
The Golgi-targeted HPV-16 E5 constructs were tested for
their ability to transform NIH 3T3 cells in focus formation
assays (Fig. 7). As shown, HPV-16 E5, 16 E5-SDYQRL
and Golgi-16 E5 did not induce foci, which also was true for
the JS55 empty vector. This result was in contrast to BPV
E5, which induced many large foci.Discussion
In this study, we generated stable fibroblast cell lines
expressing epitope-tagged BPV-1 E5 and HPV-16 E5
proteins at the same level in order to determine whether
any biological activities of BPV E5 are intrinsic to HPV-16
E5. The similar expression level of these proteins relied on
the replacement of infrequently used codons in the HPV-16
E5 gene with commonly used synonymous codons (Dis-
brow et al., 2003). The six-amino-acid AU1 epitope used for
immunological detection of the E5 proteins does not
interfere with known biological activities of BPV E5
(Sparkowski et al., 1994) and HPV-16 E5. Like the native
protein, AU1-tagged HPV-16 E5 forms homodimers,
enhances EGF-R activation in primary human keratinocytes
and induces anchorage-independent growth in murine
fibroblasts (Disbrow et al., 2003 and this study). In addition,
AU1-tagged HPV-16 E5 inhibits endosomal acidification in
human keratinocytes (Disbrow et al., submitted for pub-
lication), as described for native HPV-16 E5 (Straight et al.,
1995).
The mechanism by which BPV E5 induces sustained
activation of the PDGF-R is known in considerable
detail. Association of a PDGF-R molecule with each
subunit of a BPV E5 dimer induces trans-phosphoryla-
tion and activation of the receptor cytoplasmic domains
Fig. 6. Immunofluorescence localization of Golgi-targeted HPV-16 E5 proteins. COS-1 cells were transfected with plasmids encoding AU1-tagged BPV E5,
HPV-16 E5, 16 E5-SDYQRL, Golgi-16 E5, or JS55 empty vector, and were processed for immunofluorescence microscopy 24 h later. Anti-AU1
immunofluorescence (red) shows localization of the E5 proteins. In cells transfected with BPV E5, 16 E5-SDYQRL, Golgi-16 E5 and JS55, the Golgi
compartment was additionally labeled using Alexa Fluor 488-conjugated wheat germ agglutinin (green). In cells transfected with HPV-16 E5, the endoplasmic
reticulum was additionally labeled using an anti-calnexin antibody (green). In all cells, DNA was counterstained with Hoechst dye 33258 (blue).
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Lai et al., 1998; Petti et al., 1991). We observed
constitutive PDGF-R tyrosine phosphorylation indicative
of activation in cells expressing BPV E5 under conditions
of serum-starvation and exponential growth. As an
additional consequence of PDGF-R activation, BPV E5-expressing cells could proliferate in a serum-independent
manner.
Like BPV E5, HPV-16 E5 can form dimers (Disbrow et
al., 2003; Gieswein et al., 2003), and can bind to the PDGF-
R, EGF-R and colony-stimulating factor-1 receptor (Hwang
et al., 1995). Nevertheless, HPV-16 E5 did not constitu-
Fig. 7. Focus-forming activities of Golgi-targeted HPV-16 E5 constructs.
NIH 3T3 cells were transfected with plasmids encoding BPV E5, HPV-16
E5, 16 E5-SDYQRL, or Golgi-16 E5 (or the empty JS55 vector) and were
cultured for 17 days as described in Materials and methods.
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serum-independent proliferation in our experiments. It may
be that HPV-16 E5 stably associates with growth factor
receptors only when both are transiently overexpressed at a
high level in COS cells (Hwang et al., 1995). The inability
of HPV-16 E5 to constitutively activate endogenous growth
factor receptors in fibroblast cell lines may indicate that
complexes of HPV-16 E5 dimers and receptors do not form
when these proteins are present at lower, more physiological
levels. This idea is supported by cross-linking experiments
that find similar numbers of EGF-R dimers in HPV-16 E5-
expressing keratinocytes and control keratinocytes in the
absence of EGF (Crusius et al., 1998).
Although constitutive, ligand-independent EGF-R acti-
vation has not been demonstrated in HPV-16 E5-expressing
cells (Crusius et al., 1998; Pim et al., 1992; Rodriguez et al.,
2000; Straight et al., 1993), enhanced ligand-dependent
EGF-R activation has been reported (Crusius et al., 1998;
Pim et al., 1992; Rodriguez et al., 2000; Straight et al.,
1993) in keratinocytes, which possess large numbers of
endogenous EGF-Rs (Gottlieb et al., 1992), and in
fibroblasts that have been engineered to express high levels
of exogenous EGF-Rs (Collins et al., 1988). In contrast,
NIH 3T3 fibroblasts express lower levels of EGF-Rs (and
PDGF-Rs) (Collins et al., 1988; Heldin et al., 1981;
Selinfreund and Wharton, 1986) and we find that HPV-16
E5 does not enhance EGF-R (or PDGF-R) activation during
acute (10 min) or prolonged (24 h) treatment with EGF (or
PDGF). In keratinocytes, enhanced EGF-R activation has
been attributed to increased recycling of internalized EGF-
Rs to the plasma membrane (Straight et al., 1993, 1995) due
to an HPV-16 E5-induced defect in endosome acidification
(Adam et al., 2000; Briggs et al., 2001; Straight et al., 1995)
or defect in the fusion of early endosomes with acidic late
endosomes (Thomsen et al., 2000). Alternatively, a different
mechanism may be involved since it has been reported that
enhanced EGF-R activation occurs too rapidly after EGF
addition to be explained by increased receptor recycling
(Crusius et al., 1998). Moreover, HPV-16 E5-expressing
cells undergo ErbB2 receptor (ErbB2-R) activation during
acute EGF stimulation, even though EGF is not a ligand for
the ErbB2-R (Crusius et al., 1998). This finding suggests
that HPV-16 E5 may induce an association of inactive
ErbB2-R monomers with active EGF-R dimers in a mannerthat activates the ErbB2-Rs as a result of trans-phosphor-
ylation. HPV-16 E5 may similarly enhance EGF-R activa-
tion during acute EGF stimulation by promoting an
association of inactive EGF-R monomers with active
dimers. Such associations of receptor molecules may require
the relatively high levels of EGF-Rs, which are present in
keratinocytes and fibroblasts that overexpress exogenous
EGF-Rs (Collins et al., 1988; Gottlieb et al., 1992).
It previously has been reported that NIH 3T3 cells
expressing low levels of HPV-16 E5 detectable only by
RNA hybridization can grow in soft agar, but do not form
foci in vitro (Straight et al., 1993). At the higher level of
expression afforded by codon optimization, HPV-16 E5 still
is unable to induce focus formation in these cells (Disbrow
et al., 2003 and this study). However, codon-optimized
HPV-16 E5 is biologically active in NIH 3T3 cells since we
have shown that it transforms them to undergo anchorage-
independent growth in soft agar. Given that HPV-16 E5
does not induce oncogenic signaling characteristic of BPV
E5, its ability to promote anchorage-independent growth
may be related to a unique biological activity, such as the
EGF-independent activation of phospholipase C-g (Crusius
et al., 1999), or ability to confer increased resistance to
apoptosis (Kabsch and Alonso, 2002).
During routine maintenance of cell lines, we observed
that the growth of HPV-16 E5-expressing fibroblasts and
keratinocytes was slower than control cells harboring empty
expression vectors (data not shown). Previous reports
linking HPV-16 E5 expression to increased cell proliferation
have shown that the mitogenic effect of HPV-16 E5 is small
in the absence of EGF supplementation (Bouvard et al.,
1994; Straight et al., 1993; Valle and Banks, 1995).
Moreover, the most profound growth-stimulatory effect of
HPV-16 E5 occurred only in cooperation with the HPV-16
E7 gene (Bouvard et al., 1994; Valle and Banks, 1995).
HPV-16 E7 is co-expressed with E5 and E6 during the early
stages of HPV infection in vivo, where the role of E5 may
be to stimulate proliferation in basal layer keratinocytes (zur
Hausen, 2002), and to enhance the ability of HPV-16 to
reprogram terminally differentiating keratinocytes to
undergo DNA synthesis in order to support viral DNA
amplification (Genther et al., 2003). Since we have shown
that HPV-16 E5 does not exhibit any of the signal
transduction properties of BPV E5 in fibroblasts when the
two proteins are expressed at the same level, future
investigations of the biological functions of HPV-16 E5
will require an analysis of its activity in keratinocytes that
co-express the HPV-16 E6 and E7 proteins.Materials and methods
Plasmid constructions
All E5 constructs used in this study were engineered to
express the six-amino-acid AU1 epitope tag at their N
F.A. Suprynowicz et al. / Virology 332 (2005) 102–113110terminus to facilitate immunological detection (Lim et al.,
1990). The cloning of BPV E5 and codon-optimized HPV-16
E5 into the pJS55 expression vector have been described
previously (Disbrow et al., 2003; Sparkowski et al., 1994). To
target HPV-16 E5 to the Golgi compartment using the Q17G
null mutant of BPV E5 (Sparkowski et al., 1994), a two-step
PCR protocol was employed. The first step generated a DNA
fragment consisting of Q17G BPVE5 appended to codons 2–
7 of HPV-16 E5, as well as a second fragment comprising the
last 6 codons of Q17G BPV E5 (excluding the stop codon)
appended to HPV-16 E5. For the first fragment, the 5V
oligonucleotide primer (Integrated DNATechnologies) con-
tained an upstream XhoI restriction site, Kozak sequence
(Kozak, 1987), ATG translational start site and first codon of
the AU1 epitope tag: 5V-CTCGAGGCCACCATGGAC-3V
(primer A). The 3Vprimer was complimentary to codons 39–
44 of Q17G BPV E5 and to codons 2–7 of codon-optimized
HPV-16 E5: 5V-TGCAGTATCCAGATTTGTAAAGGGCA-
GACCTGTACA-3V(primer B). The 5Vprimer for the second
fragment corresponded to codons 39–44 of Q17G BPV E5
and codons 2–7 of codon-optimized HPV-16 E5: 5V-
TGTACAGGTCTGCCCTTTACAAATCTGGA -
TACTGCA-3V(primer C). The 3Vprimer was complimentary
to the last six codons of codon-optimized HPV-16 E5
(including the stop codon) and to a downstream HindIII
restriction site: 5V-AAGCTTTTATGTAATCAGAAAGCG-3V
(primer D). The two PCR products were purified from
agarose gels and directly used as templates for the second
PCR reaction, together with oligonucleotide primers A and
D. This reaction generated full-length Q17G BPV E5
appended to full-length, codon-optimized HPV-16 E5
(Golgi-16 E5), which was ligated into pGEM-T (Promega)
for amplification and sequencing, and was then cloned into
the XhoI and HindIII restriction sites of pJS55. A one-step
PCR was employed to append the Golgi retrieval signal,
SDYQRL (Roquemore and Banting, 1998), to the C terminus
of codon-optimized HPV-16 E5 (16 E5-SDYQRL). The 5V
primer for this reaction was 5V-TTACATGGATCCGCCAC-
CATGGACACCTATCGCTATATAACAAATCTGGAT-3V,
which contained a BamHI restriction site, Kozak sequence,
start codon and AU1 epitope tag. The 3V primer was 5V-
GCGGCCGCCTACAAACGTTGGTAGTCACTTGTAAT-
CAGAAAGCGTGC-3V, and included sequences compli-
mentary to a stop codon and downstream NotI restriction
site. Codon-optimized HPV-16 E5 (in pJS55) served as the
DNA template for PCR. The 16K subunit of the bovine
vacuolar H+-ATPase has been cloned into the expression
vector pSVL with the 11-amino-acid HA epitope tag at its N
terminus (Andresson et al., 1995).
Cell culture and transfection
NIH 3T3 cell lines and COS-1 cells were maintained at
37 8C in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% FBS, 100 U/ml penicillin G and
100 Ag/ml streptomycin sulfate (Invitrogen). For analysis ofsignaling proteins under reduced serum conditions, 15-cm
tissue culture dishes of 50% confluent cells were washed
twice with 25 ml Dulbecco’s phosphate-buffered saline
(PBS) and cultured in 25 ml DMEM containing 0.1% FBS
for 24 h. NIH 3T3 cell lines stably expressing E5 proteins
were obtained following puromycin selection of cells co-
transfected with E5 constructs and the puromycin resist-
ance-conferring plasmid, pBABEpuro (Morgenstern and
Land, 1990), at a ratio of 9:1 (E5 DNA: pBABEpuro) as
described previously (Suprynowicz et al., 2002). At least 50
puromycin-resistant colonies were pooled for each cell line.
Prior to transfection, COS-1 cells were grown to 80%
confluence in 10-cm tissue culture dishes in Opti-MEM
medium (Invitrogen) containing 4% FBS. For each 10-cm
dish, 32 Ag DNA was mixed with 4 ml serum-free Opti-
MEM and 40 Al Lipofectamine 2000 transfection reagent
(Invitrogen) and was added to the cells for 4 h.
To assay growth-factor-independent proliferation of NIH
3T3 cell lines, 6-cm tissue culture dishes were seeded with
1.5  104 cells in 4 ml (DMEM + 2% FBS). After 24 h,
dishes were washed twice with PBS and the medium
replaced with 4 ml (DMEM + 0.3% FBS) for 3 days. At the
beginning and end of this 3-day period, cells were detached
from duplicate dishes using trypsin/EDTA treatment, and
were counted in a Beckman-Coulter particle counter.
Results were calculated as the percent increase in number
of cells while in 0.3% FBS.
Transformation assays
The focus forming activities of E5-expressing cell lines
were assayed by plating 500 E5-expressing cells with
5  105 normal NIH 3T3 cells as detailed previously
(Suprynowicz et al., 2002). The focus forming activities of
Golgi-targeted HPV-16 E5 constructs were analyzed by
transfecting 10-cm tissue culture dishes of 80% confluent
NIH 3T3 cells using the Lipofectamine 2000 procedure
outlined above. Following transfection, the medium was
replaced with (DMEM + 10% FBS). After 3 days, the cells
were replated in 175-cm2 tissue culture flasks, which were
maintained for 2–3 weeks with additions of fresh medium
every 3 days. Foci were stained with 1% methylene blue
(Sigma) as described (Suprynowicz et al., 2002). Where
indicated, purified PDGF or EGF (Invitrogen) also were
added to cultures every 3 days.
Anchorage-independent growth was assayed in 3.5-cm
tissue culture dishes by layering 1.7  104 cells in 1 ml
DMEM containing 10% FBS and 0.3% (w/v) agarose over 1
ml DMEM containing 10% FBS and 0.6% (w/v) agarose
(Suprynowicz et al., 2000).
Immunofluorescence microscopy
COS-1 cells were grown to 80% confluence on 22  22
mm glass cover slips in six-well cluster plates containing
Opti-MEM + 4% FBS. For transfection, 4 Ag DNA was
F.A. Suprynowicz et al. / Virology 332 (2005) 102–113 111mixed with 0.5 ml serum-free Opti-MEM and 5 Al
Lipofectamine 2000 and was added to each well for a
period of 4 h. Twenty-four hours later, cells were fixed in
4% paraformaldehyde (25 min), permeabilized in PBS
containing 0.1% (w/v) saponin (10 min) and blocked in
Pgel-S (PBS + 0.2% (w/v) gelatin + 0.1% saponin)
containing 10% normal donkey serum (20 min). Cells were
labeled for 30 min with primary antibodies diluted in Pgel-
S: anti-AU1 ascites (Covance) at 1:150 and anti-calnexin
rabbit polyclonal IgG (Santa Cruz) at 2.5 Ag/ml. After four
washes with PBS, rhodamine-conjugated donkey anti-
mouse IgG and fluorescein-conjugated donkey anti-rabbit
IgG (Jackson Laboratories) were applied for 30 min (1:100
dilutions in Pgel-S). Cells were washed twice with PBS
containing 0.2% gelatin and twice with PBS before
mounting in 9:1 glycerol/PBS containing 5% (w/v) n-propyl
gallate. The Golgi compartment was labeled using Alexa
Fluor 488-conjugated wheat germ agglutinin (Molecular
Probes) at 1 Ag/ml in Pgel-S. DNA was stained using
Hoechst dye 33258 (Sigma) at 0.5 Ag/ml in PBS.
Metabolic labeling
Ten-centimeter dishes of 80% confluent cells were
washed with PBS (15 ml per dish) and incubated for 2 h
in DMEM without cysteine and methionine (4 ml per dish;
BioSource International). [35S] methionine/[35S] cysteine
protein labeling mix (Perkin-Elmer bEasy TagQ) was added
(200 ACi per dish) for a period of 3 h, and the cells
subsequently lysed in modified RIPA buffer as described
below.
Immunoprecipitation and immunoblotting
Phosphotyrosine-containing proteins were immunopreci-
pitated from SDS lysates of 80–90% confluent 15-cm tissue
culture dishes as detailed previously (Suprynowicz et al.,
2000). AU1-tagged E5 proteins were immunoprecipitated
using the same protocol (10 Al anti-AU1 ascites per 0.75–
1.5 mg cell lysate), except that cells were lysed in a
modified RIPA buffer (150 mM NaCl, 1 mM EDTA, 1%
Nonidet P-40, 1% deoxycholate, 0.1% SDS, 20 mMMOPS-
NaOH, pH 7.0, 0.5 mM phenylmethylsolfonyl fluoride,
2 Ag/ml aprotinin, 2 Ag/ml leupeptin and 2 Ag/ml pepstatin).
Immunoprecipitates were fractionated on 1.5-mm SDS
polyacrylamide mini-gels (Invitrogen), transferred to Immo-
bilon-P membranes (Millipore) and labeled with polyclonal
antibodies (Upstate Biotechnology, Inc.) recognizing the
PDGF-R, EGF-R, or 85 kDa regulatory subunit of PI 3-K as
previously described (Suprynowicz et al., 2000, 2002). The
same method was used to label anti-AU1 immunoblots,
except that three labeling steps were employed: anti-AU1
acsites diluted 1:2000, unconjugated rabbit anti-mouse IgG
(Pierce) at 1 Ag/ml and alkaline phosphatase-conjugated
goat anti-rabbit IgG (Applied Biosystems) diluted 1:5000.
Anti-HA immunoblots were blocked with 2% (w/v) bovineserum albumin in PBS containing 0.05% (w/v) Tween-20,
and were labeled with 1:5000-diluted anti-HA ascites
(Covance) and alkaline phosphatase-conjugated goat anti-
mouse IgG.
Src kinase assay
c-Src immunoprecipitates were incubated in the presence
of [g-32P]ATP and the selective substrate peptide KVEKI-
GEGTYGVVYK (Cheng et al., 1992) as described pre-
viously (Suprynowicz et al., 2002).Acknowledgments
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